Acorda Therapeutics (ACOR) Misses Q4 EPS by 102c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall St slides after strong jobs report bolsters hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil slides on Friday, heads for weekly gain on US-Iran fight
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Acorda Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
March 4, 2021 4:01 PM ESTSale of Manufacturing Operations to Catalent with net proceeds of ~$74 million Annual operating expenses cut by ~$40 million via sale, restructuring, and other reductions Total 2021 non-GAAP operating expense expected to be $130-$140 million1 AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg 2021 net revenue expected to be $75-$85 million INBRIJA® (levodopa inhalation powder) 2020 net revenue $24 million AMPYRA 2020 net revenue $99 million
ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a business update and reported its financial results for the fourth quarter and full... More
